"We are also expanding our presence in the United States with significant investments in research, development and manufacturing," said Pascal Soriot, AstraZeneca’s Chief Executive Officer.
Soriot added AstraZeneca is "committed to working with PhRMA and policymakers to ensure the U.S. remains the global leader in biomedical innovation and that medicines are affordable for everyone who needs them."
In May 2023, the London-listed company had decided to leave the group and explore alternative advocacy approaches at both state and federal levels.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.